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Objectives. The main aims of treatment in patients with intermittent claudication (IC) are to improve the clinical indi-
cators of lower limb ischaemia and patients’ quality of life (QoL). The aims of this study were assess the clinical and cost
effectiveness of a supervised exercise programme (SEP) in patients with IC.
Design. Non-randomised, controlled trial.
Setting. University teaching hospital.
Patients and methods. Two groups of patients with IC were studied. Seventy patients were sequentially recruited before
and after the establishment of a Supervised Exercise Programme at our unit. Thirty-seven patients (median age 69 years,
26 men) received conservative medical therapy (CMT) and 33 patients (median age 67 years, 22 men) received CMT plus
a 3 month SEP of graduated physical exercise for sixty minutes, three times each week. Patients were assessed prior to and
at 6 months following treatment. At each assessment patient reported walking distances (PRWD), treadmill claudication
and maximal distances (ICD and MWD), ankle brachial pressure indices (ABPI) pre & post exercise and patient reported
QoL using the SF36 questionnaire were assessed.
Results. Prior to intervention the two groups were well matched. Following treatment, CMT patients demonstrated no
significant change in PRWD or ICD but did record a small but significant improvement in MWD. CMT was also asso-
ciated with a negative effect size in the SF36 index and in 7 of the 8 SF36 QoL domains, effect size >0.5 for the domains
of Physical Function and Emotional Role. SEP patients demonstrated significant improvement in PRWD, ICD and MWD.
SEP was associated with a positive effect size in the SF36 index and in 2 SF36 QoL domains but a negative effect size in
a further 2 domains. However, all QoL effect sizes following SEP were < 0.5. Intergroup differences in effect sizes were
>0.5 for the SF36 domains of Physical Function, Physical Role, Emotion Role and SF36 index. SEP resulted in a 0.027
quality adjusted life year (QALY) gain over CMT in the first year post-treatment thus the cost/QALY gained of SEP is
£1780 at 1 year.
Conclusions. Compared to CMT, SEP increases walking distances, improves QoL and is a highly cost-effective treatment
for IC.
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Peripheral arterial disease increases with age affect-
ing 5% of the population aged 55 years, resulting
in serious quality of life (QoL) limitations.1,2 Current
treatment of intermittent claudication (IC) is multi-
modal and variable. Risk factor modification should
be mandatory as the major cause of mortality in
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peripheral arterial disease itself.3e5 Specific therapy
for IC should aim to improve patients QoL in addi-
tion to the clinical indicators of lower limb ischae-
mia whilst providing value for money. Exercise is
generally recommended for patients with IC who
are advised to walk to and beyond their ischaemic
pain. Supervised Exercise Programmes (SEP) for
claudicants have been demonstrated to be beneficial
in terms of improved walking distances but are not
universally available.6e8 This may be due to the
paucity of supportive QoL9 and health economic
data. The aims of this study were to assess whether
SEP for IC improves patients QoL and is cost
effective.rved.
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Patients
70 patients with intermittent claudication were re-
cruited sequentially into the study from a vascular
outpatient clinic setting. Patients were divided in re-
cruitment into those recruited before and after the es-
tablishment of a Supervised Exercise Programme
(SEP) at our unit. Thirty-seven patients (median age
69 years, 26 men) received Conservative Medical
Therapy (CMT) as they were recruited prior to the es-
tablishment of our SEP. These patients were followed
by 33 subjects (median age 67 years, 22 men) recruited
during the early stages of the SEP. These later patients
received CMT plus a 3 month Supervised Exercise
Programme (SEP).
Intervention
Conservative medical therapy
Patients undergoingCMTwereprescribed an antiplatelet,
receivedsmokingcessationadviceandsupport (including
nicotine replacement therapy), and risk factor modifica-
tion (appropriate management of hypertension, hyper-
cholesterolaemia and diabetes according to evidence
based care pathways within a dedicated clinic). All pa-
tients also received an advice leaflet regarding exercise.
Supervised exercise therapy
In addition to CMT, SEP patients attended three ses-
sions of supervised exercise per week, for a total of
twelve weeks. Each session consisted of alternating
exercise stations of two minutes each, with walking
circuits of two minutes in between exercise stations.
The duration of exercise sessions was six stations for
the first six weeks, increasing by one station per
week thereafter. By end of the exercise programme,
patients were completing twelve stations per session.
There were six exercise stations, arranged in the
following order:
Station 1: Walking up and down a six-inch step.
Patients started with the left foot first, then
changed the starting foot every ten steps. This was
continued for two minutes.
Station 2: Double heel raise.
Standing erect, with both feet flat on the floor and
holding hardrails for support, patients stood on tip-
toes. This was held for approximately two seconds,
then the patient slowly returned their weight to the
floor. Repeated for two minutes.
Station 3: Single leg press.
Patients stood on one leg between two parallel bars,
used for stability (but not weight-bearing). During thetwo-minute duration of this exercise, patients lowered
their weight by bending at the standing leg, then
straightened the leg against their own weight. After
ten repetitions, the contralateral leg was exercised.
Station 4: Exercise bicycle.
The patients pedalled for two minutes on an exer-
cise bicycle. Exercise resistance was sufficient to pro-
duce perspiration and dyspnoea, but still allowing
conversation in complete sentences.
Station 5: Knee extension.
Patients sat on a high stool, knees flexed, with
2.5 kg weights attached to each ankle. One leg was
slowly straightened to maximum extension, before be-
ing slowly returned to 90 degrees of flexion. Each leg
was exercised in ten times in this manner, in alter-
nating fashion for two minutes.
Station 6: Elbow flexion.
Whilst holding 1.5 kg dumbbells, patients flexed
and extended their elbows for 2 minutes.
Assessments
Were performed prior to, and at 6 months following
treatment. At each assessment, the following outcome
measures were analysed.
Clinical indicators of lower limb ischaemia; Patient
Reported Walking Distance (PRWD) was recorded. Pa-
tients were subjected to a standard treadmill walking
test (2.4mph, 10 degree incline) to gauge treadmill Initial
Claudication (ICD) and Maximal Walking Distances
(MWD). Ankle Brachial Pressure Indices (ABPI) were
recorded prior to and following treadmill testing.
Quality of life; was measured with the generic
SF36 questionnaire. The SF36 produces a global in-
dex score and scores for 8 QoL domains: physical
function (PF); role physical (RP); bodily pain (BP);
vitality (Vit); social function (SF); mental health
(MH); role emotional (RE) and general health
(GH). Each domain is scored from 0 (worst
health)e100 (best health) whilst the index is scored
from 0 (worst health)e1 (best health). The validity,
reliability and responsiveness of the SF36 in popula-
tion studies and specifically in patients with lower
limb ischaemia have been demonstrated.2
Cost effectiveness analysis
The SF36 index score was plotted over time for both
groups of patients. Changes for 0 to 6 months were
measured during the study and changes between
6 and 12 months were extrapolated. These extrapola-
tions were based on previous studies using QoL out-
comes in patients undergoing SEP.10,11 Calculating the
difference in Areas Under both Curves (AUC) gave
the incremental QALY gain. Marginal costs to the
NHS were obtained from the local NHS Hospital TrustEur J Vasc Endovasc Surg Vol 33, February 2007
204 H. L. D. Lee et al.finance department. Dividing the marginal cost per
patient by the QALYs gained for SEP gave the cost/
QALYvalue for SEP.
demonstrate the relative importance of a treatment
effect within a study.12Statistical analysis
Standard tests
Data was entered into a spreadsheet (Microsoft Excel
95) and statistical analysis was performed using
a commercially available statistics software package
(SPSS version 11.5, SPSS Inc, Chicago, IL, U.S.A.).
As the number of patients was small and data not
normally distributed, non-parametric statistical tests
were used. Clinical indicators of lower limb ischaemia
were expressed as a medians inter quartile range.
Inter group analysis at baseline and at 6 months
(Wilcoxon matched pair test) and intragroup analyis
(Mann Whitney U test) comparing results pre and
post treatment was performed. p values  0.05 were
considered to be statistically significant.
Quality of Life
QoL results are presented as effect sizes calculated
by subtracting the pre treatment median from the
post treatment median and dividing by the pre
treatment interquartile range. An effect size 0.5 is
considered to represent clinical significance. Effect
sizes have been strongly recommended for interpre-
tation of QoL changes in health care, in order toEur J Vasc Endovasc Surg Vol 33, February 2007Results
Patients (Table 1)
Patients groups were well-matched pre-treatment.
The only significant difference in the clinical indica-
tors of lower limb ischaemia between the two groups
was in the initial patient reported walking distance.
The only significant difference in SF36 domain/index
scores were in the SF36 domains of BP and GH with
higher scores in the SEP group.
Clinical indicators of lower limb ischaemia (Table 1)
CMT patients
No significant improvements were reported in
PRWD, ICD, ABPI pre or post treadmill testing
but there was a small but significant improvement
in MWD.
SEP patients; demonstrated significant improve-
ments in PRWD, ICD and MWD but no significant
improvement in ABPI pre or post treadmill testing.
Intergroup analysis; The magnitude of improvement
in PRWD, ICD and MWD following SEP exceeded
that following CMT.Table 1. Effect of treatment on clinical indicators and SF36 QoL domains
CMT SEP
Pre Post Pre Post
Median age (range)/years 69 (60.8e75.8) 67 (61.0e72.8)
Men:Women 26:11 22:11
PRWD (metres) 200 (100e600) 225 (50e600) 100 (50e300)þ 600 (300e1200)*þ
ICD (metres) 78.4 (39.2e131.3) 75 (45.0e180) 58.5 (39.2e112.7) 107.5 (52.5e153.8)*þ
MWD (metres) 152.2 (76.7e279.3) 185 (102.0e300.0)* 117.6 (73.5e205.8) 300.0 (143.8e300.0)*þ
ABPI e rest 0.69 (0.56e0.84) 0.77 (0.64e0.86) 0.68 (0.55e0.89) 0.71 (0.60e0.80)
ABPI e post exercise 0.64 (0.51e0.81) 0.57 (0.44e0.81) 0.63 (0.44e0.81) 0.64 (0.49e0.79)
SF36 PF 52.5 (45.0e70.0) 37.5 (11.3e63.8) 45.0 (25.0e62.5) 50.0 (35.0e67.5)
SF36 PR 25.0 (0.0e100.0) 0.0 (0.0e75.0) 0.0 (0.0e75.0) 25.0 (0.0e87.5)
SF36 BP 31.0 (22.0e60.0) 32.0 (22.0e52.0) 52.0 (42.0e69.0)þ 42.0 (31.0e52.0)
SF36 GH 52.0 (40.0e60.0) 47.5 (31.25e67.0) 65.0 (52.0e72.0)þ 60.0 (47.0e52.5)
SF36 Vit 55.0 (40.0e62.0) 45.0 (32.5e57.5) 55.0 (50.0e70.0) 55.0 (50.0e60.0)þ
SF36 SF 53.8 (45.6e75.0) 50.0 (43.8e65.0) 50.0 (43.8e56.2) 50.0 (40.0e52.5)
SF36 ER 100.0 (8.3e100.0) 50.0 (0.0e100.0)* 66.7 (16.7e100.0) 66.7 (16.7e100.0)
SF36 MH 64.0 (56.0e75.0) 60.0 (46.0e68.0)* 64.0 (56.0e72.0) 64.0 (56.0e72.0)
SF36 index 0.615 (0.547e0.655) 0.595 (0.547e0.650) 0.600 (0.570e0.645) 0.630 (0.570e0.650)
PRWD: Patient Reported Walking Distance; ICD: Initial claudication distance on treadmill testing; MWD: Maximal walking distance on
treadmill testing. ABPI Rest: ABPI at rest; ABPI Post-exercise: ABPI following treadmill testing; SF36-PF: Physical Function; SF36-PR:
Role Physical score; SF36-BP: Bodily Pain; SF36-GH: General Health score; SF36-Vit: Vitality; SF36-SF: Social function score; SF36-ER:
Role Emotional score; SF36-MH: Mental Health; SF36 Index: Index score. Results presented as median [IQR].
* p<0.05 intra-group analysis, Wilcoxon signed rank test.
þ p<0.01 inter-group analysis, Mann-Whitney U test.
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Fig. 1. Effects sizes for SF36 Domains and Index Score.Short Form 36 results (Fig. 1)
CMTpatients; demonstrated significant deterioration in
the SF36 domains of ER and MH. CMTwas also asso-
ciated with a negative effect size in the SF36 index and
in 7 of the 8 SF36 QoL domains, effect size >0.5 for
the domains of Physical Function and Emotional Role.
SEP patients; demonstrated no significant changes
in the SF36 domains or index. Effect sizes following
SEP were positive for the SF36 index and in 2 SF36
QoL domains (PF and RP) but negative in a further
2 domains (BP and GH). However, all QoL effect sizes
following SEP were < 0.5.
Intergroup analysis SF36 Vitality significantly im-
proved following SEP compared to CMT. Intergroup
differences in effect sizes were >0.5 for the SF36 indexand the SF36 domains of Physical Function, Physical
Role, Emotional Role.
Cost-effectiveness analysis (Fig. 2)
The area under each curve signifies total QALY for each
patient group. The difference in area under the two
curves denotes incremental QALYs gained. Plotting
QALY curves for both groups of patients, then calculat-
ing theAUCbetween themgives an incremental gain of
0.027QALYs gained in the first year. Costs for SEPwere
obtained from the Finance Department of the Hull
Royal Infirmary. Three hours of supervised exercise
per week for one year cost GBP2306.88. Each session
can accommodate twelve patients, for three months,0 1261.8 Time
(months)
0.600
0.609
0.615
0.630
SF36
index
A
B
Measured QoL with CMT  Measured QoL with SEP  
Hypothesised QoL with CMT Hypothesised QoL with SEP  
Fig. 2. QALYs gained. Shaded area represents QALYs gained. Therefore for first year, patient gains 0.027 QALYs (Areas
AþB).Eur J Vasc Endovasc Surg Vol 33, February 2007
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a three-month SEP, assuming full recruitment. The
cost/QALY for a 3 month SEP in the first year is
GBP1780, given a gain of 0.027 QALY per year, at
a cost of GBP48.06 per patient.
Discussion
In this era of evidence based care and limited re-
sources, any interventions by necessity must be both
clinically and cost effective. SEP for claudication
improves walking distances, however the main treat-
ment objective is to improve overall QoL. It cannot be
assumed that improvements in the clinical indicators
of lower limb ischaemia are mirrored by reciprocal
QoL changes as it has been clearly demonstrated
that correlation between the two is relatively poor.
QoL improvements therefore cannot be inferred and
must be actually documented. The impact of SEP on
QoL in claudicants with appropriate controls has not
been previously studied. Previous studies have ana-
lysed the impact of SEP on symptoms and walking
distances but not QoL,13 and the impact of unsuper-
vised exercise on QoL.10 Ours is the first study to
demonstrate SEP for claudication is associated with,
marked improvement in walking distances, modest
improvements in physical QoL domains and preven-
tion of the deterioration in the psychological QoL do-
mains associated with CMT. The fall in bodily pain
(signifying greater pain burden) with SEP, although
not attaining statistical or clinical significance, we
found interesting. This may signify patients following
SEP are more willing to walk further with pain per-
haps being reassured by SEP participation. More
marked changes in QoL may have been demonstrated
if we had used a disease specific rather than generic
QoL instrument, which are generally accepted to be
more sensitive to change. Health economic evalua-
tion, however is currently only possible with generic
instruments. In addition in the future we hope to
compare the clinical & cost effectiveness of SEP for
claudication with other interventions for common,
non vascular, conditions.
The changes in the SF36 index for the first 6 months
were measured, whereas the changes in the second six
months were hypothesised using best available data.
Previous SEP studies, several with more prolonged
follow up, essentially demonstrate the benefits seen
at 6 months in clinical indicators and QoL, persist
but diminish.7,9e11,13 The specific rate of QoL deterio-
ration following SEP cessation varies between studies.
We have assumed QoL following cessation of SEP de-
teriorates at the same rate as in CMT patients. If theEur J Vasc Endovasc Surg Vol 33, February 2007rate of decline was slower following SEP cessation
this would further increase the incremental QoL
gain and cost-effectiveness of SEP.
National Institute for Clinical Excellence (NICE)
guidelines for best practice in the United Kingdom,
with respect to cost per QALY gained, states that in
order for a treatment to be regarded as cost-effective,
the cost must fall to below GBP30000.00 per QALY
gained. We can therefore claim SEP for claudication
is highly cost effective.
Our sample of patients was recruited sequentially,
although there were minimal differences between the
two groups of patients, we would recommend rando-
mised controlled studies in the future. In addition pro-
longed, multiple follow up points are suggested.
There areno existing trials examining the question of
re-treatment with SEP. Patients who have previously
benefited from SEP may benefit from a repeat SEP.
This requires further investigation. In conclusion, SEP
in patients with intermittent claudication improves
the clinical indicators of lower limb ischaemia, im-
proves physical QoL domains& prevents deterioration
in psychological QoL. Health economic analysis dem-
onstrates SEP is an extremely cost-effective treatment
for claudication. We are currently recruiting into a ran-
domized controlled trial with calculated sample sizes
and longer follow-up periods. The effects of repeat or
‘booster’ SEP treatments also need to be explored.
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